Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
In line with a tumor-suppressive role, ARF-deficient mice develop lymphomas, sarcomas, and adenocarcinomas, with a median survival rate of one year of age.
|
30836703 |
2019 |
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
In the present study, the methylation status of the promoter regions of protein tyrosine phosphatase (PTPN) 6, DAPK, and p16 were studied using methylation-specific polymerase chain reaction (MSP) in 26 diffuse large B cell lymphoma (DLBCL) lymphomas.
|
26498513 |
2016 |
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
Following the finding that the p16 antitumor peptide dramatically inhibits the growth of aggressive leukemia/lymphoma through the restoration of p16 function using the Wr-T peptide transporter system, in this study, we developed a systemic therapy using mouse‑p16 peptide (m‑p16) in subcutaneous p16‑null mouse bladder tumors.
|
23292502 |
2013 |
Lymphoma
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Several studies have shown that CDKN2A and CDKN2B deletions are frequent in these lymphomas.
|
21638516 |
2011 |
Lymphoma
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Fluorescent in situ hybridization (FISH) analysis was performed to confirm CGH array data and to detect lymphoma-associated gene rearrangements. p14(ARF)/p16(INK4a) CDKN2A gene quantification, methylation analysis, and immunohistochemical detection were also performed.
|
18311490 |
2008 |
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
Methylation of DAPK and p16(INK4a) genes is a frequent event in this lymphoma at its initial presentation, but may not be associated with tumor progression.
|
18820662 |
2008 |
Lymphoma
|
0.500 |
PosttranslationalModification
|
group |
BEFREE |
Seven of seven PCLBCL, leg type, patients with deletion of 9p21.3 and/or complete methylation of CDKN2A died as a result of their lymphoma.
|
16330669 |
2006 |
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
Further studies are needed to determine whether p16 is widely suppressed in immunosuppression-induced lymphoma.
|
17052484 |
2006 |
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
Acute MYC expression increases p53 or ARF levels and induces apoptosis, and previous transgenic animal studies revealed frequent inactivating mutations of p53 or p19ARF in transgenic Myc-induced lymphomas.
|
16169462 |
2005 |
Lymphoma
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Our observation of frequent p14 gene abnormalities (90%) and inactivation (40-60%) was in striking contrast to the same pathological subtype of systemic lymphoma in which p14 gene abnormalities and inactivation were infrequent, suggesting a difference in carcinogenesis between PCNSL and systemic lymphoma.
|
15649253 |
2005 |
Lymphoma
|
0.500 |
PosttranslationalModification
|
group |
BEFREE |
Silencing of p16/INK4A expression is frequently caused by hyper-methylation of CpG islands in its promoter but may also be achieved through activation of Bmi-1, for example in lymphomas associated with the E2A-Pbx1 translocation.
|
15611658 |
2005 |
Lymphoma
|
0.500 |
PosttranslationalModification
|
group |
BEFREE |
Methylation of the p15INK4b promoter never seems to occur in solid tumors but is a major gene silencing mechanism in hematological malignancies. p14ARF and p16INK4a promoter methylation often occurs in solid tumors but also in leukemias and lymphomas.
|
15370242 |
2004 |
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
Deletions at chromosome 9p21, which harbours the tumour suppressor genes p14/ARF, p15/INK4b, and p16/INK4a, and 17p13, where p53 is located, are associated with the development and progression of lymphomas.
|
14743509 |
2004 |
Lymphoma
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Acute/lymphomatous ATLL has frequent alterations of p15 (20%) and p16 (28-67%), while chronic/smoldering ATLL has fewer abnormalities of p15 (0-13%) and p16 (5-26%).
|
12040438 |
2002 |
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
In addition, homozygous deletions of p15, p16 and p14 genes in 5 out of 31 samples were detected; 3 were from nasal NK cell lymphoma and 2 from blastic NK cell lymphoma / leukemia.
|
11676855 |
2001 |
Lymphoma
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Thus, unlike the p16 and p15 tumor suppressor genes, which are frequently deleted and inactivated in brain lymphoma and represent a striking contrast to systemic lymphoma, MMAC1 may not play an important role in carcinogenesis in this tumor, as in the systemic counterpart.
|
11908870 |
2001 |
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
Loss of INK4a/alternate reading frame (ARF) in mice is associated with increased incidence of other tumors such as lymphoma and fibrosarcoma.
|
11719444 |
2001 |
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
Frequent alterations of the p14(ARF) and p16(INK4a) genes in primary central nervous system lymphomas.
|
11522621 |
2001 |
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
The two patients with p16 loss both died of lymphoma, whereas the two patients with normal p16 expression are alive.
|
10976700 |
2000 |
Lymphoma
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Whether p16 deletion in these lymphomas is associated with disease progression and whether this method could serve as an early marker to detect lymphomas at an early stage needs to be addressed in future studies.J Invest Dermatol 115:1104-1107 2000
|
11121148 |
2000 |
Lymphoma
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Furthermore, low E2F-1 expression and p16INK4A inactivation may serve as prognostic markers for patients with this type of lymphoma.
|
10803523 |
2000 |
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
Tumors with concomitant alterations of p16(INK4a) and p14(ARF)/p53 genes seem to exhibit a worse clinical behavior than lymphomas with no alterations or isolated inactivation of any of these genes.
|
10854221 |
2000 |
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
Furthermore, INK4a/ARF(-/-) lymphomas displayed reduced p53 activity despite the presence of wild-type p53 genes.
|
10541553 |
1999 |
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
We found no mutations of p15, p16, or p14 in any of the 56 lymphomas.
|
10477703 |
1999 |
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
These findings suggest that p16 gene abnormality and inactivation are closely related to carcinogenesis in primary malignant lymphoma of the brain.
|
9515810 |
1998 |